Page 36 - GTM-2-1

Global Translational Medicine Stem cells in aortic aneurysm

Table 2. (Continued)
Cell type Delivery Injection time Number of AA model Total time Efficiency References
cells
microRNA-147 during the initiation and
development of AAA
BM-MSC IV injection Week 0,1,2,3 1×10 /every Ang II-infusion 4 weeks Multiple intravenous administrations [106]
6
time mice AA model of BM-MSCs were effective to inhibit
the inflammatory reactions in Ang
II-induced AA in apoE mice
-/-
MSCs-CM IV injection Day 0,3,6,9,12 / Ang II-induced 14 days MSCs-CM regulates the polarization [60]
mice model of M1/M2 macrophages to effectively
alleviate Ang II‐induced AA growth
BM-MSC IV injection Day 0 1×10 6 Ang II-infusion 2 weeks BM-MSCs regress AA via regulation of [107]
mouse model the NF-κB, Smad3 and Akt signaling
pathways
BM-MSC Catheter 14 days after / The xenograft AAA 7 days Cell therapy reconstructs the mechanical [108]
xenograft rat model properties of the damaged abdominal
implantation aorta by improving tissue stiffness,
stabilizes the geometry of AAA and
reduces pressure changes in the artery
wall
ADSC-exos IV injection Every 3 days 100 μg/every Ang II-infusion 28 days MiR-17-5p-rich ADSC-exos constraining [68]
time mouse AAA model AAA progression and inflammatory
cytokines release, via the TXNIP-NLRP3
signaling pathway
Human Tail vein Day 1 A total of Elastase-inducing 14 days MSCs significantly reduce AAA [61]
Placental injection 1×10 6 mice AAA model formation by immunomodulating
MSC IL-17-mediated inflammatory processes
AA: Aortic aneurysm; TAA: Thoracic aortic aneurysms; AAA: Abdominal aortic aneurysm; MSC: Mesenchymal stem cell; BM-MSC: Bone
marrow-derived MSC; UC-MSCs: Umbilical cord mesenchymal stem cells; ADSC: Adipose tissue-derived stromal cells; Muse
cells: Multilineage-differentiating stress-enduring cells; EV: Extracellular vesicles; MSCs-CM: MSC–derived conditioned medium;
ADSC-exos: ADSC-derived exosomes; IV: Intravenous; Ang Ⅱ: Angiotensin II; HMGB1: High mobility group box 1; VSMC: Vascular smooth muscle
cells; EC: Endothelial cells; MMP: Matrix metalloproteinase; TNF-α: Tumor necrosis factor-α; ASC: Adipose tissue-derived stromal cells; RCP: A
recombinant collagen-based patch; IGF-1: Insulin-like growth factor-1; TIMP-2: Tissue inhibitor of metalloproteinase-2; apoE : Apolipoprotein
-/-
E-deficient; NF-κB: Nuclear factor kapp B; Smad: Sma- and Mad-related proteins; Akt: Protein kinase; miR-17-5p: microRNA-17-5p;
TXNIP: Thioredoxin-interacting protein; NLRP3: NOD-like receptor thermal protein domain associated protein 3; IL-17: Interleukin-17
preserving elastin in the aortic wall. It can reduce MMPs can also significantly attenuate the development of AAA
and inflammatory cytokine levels , for example, reducing in mice by inhibiting AAA formation and inhibiting
[85]
MCP-1, TNF-α, IL-6, and MMP-2/9 but increasing TIMP- inflammation and promoting ECM synthesis .
[91]
1/2 . In terms of the delivery mode, the safety and Muse cells were injected intravenously in a mouse AA
[86]
feasibility of the NOGA (a company in USA) system for model, and then they were found selectively migrated
intravascular delivery of MSCs to the aortic wall in a AAA and integrated into the AA tissue. Subsequently, Muse
porcine model have been confirmed . MSCs not only cells can spontaneously differentiate into VSMCs and
[87]
inhibit inflammation but also act on damaged VSMCs. endothelial cells while retaining elastic fibers and
[92]
Studies have shown that intravenous administration of inhibiting inflammation . Muse cells are characterized
[93]
human umbilical cord MSCs can maintain or restore by significantly reducing the diameter of AA compared to
[88]
the VSMC contractile phenotype in AAA . VSMCs
generated by MSC can stimulate the synthesis of aneurysm non-Muse cells. Hence, muse cell is a promising cell type
for AA treatment.
VSMCs to compensate for dead VSMCs and provide elastic
power for aneurysm VSMCs . For example, the use of Recently, ADSC has also been studied in the field of
[89]
PDGF + TGFβ1-induced BM-MSC or ADSC-derived treatment of AA. ADSCs have the characteristics of easy
VSMCs in tissue sites affected by vascular diseases such culture and expansion, pluripotency and differentiation ability,
as AAA can achieve complete autologous therapy . and the ability to produce trophic factors. Hence, ADSC has
[90]
Mesenchymal stem cell-derived exosomes (MSC-exs) the potential for clinical application in the treatment of AA .
[94]
Volume 2 Issue 1 (2023) 11 https://doi.org/10.36922/gtm.v2i1.241